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interval [CI]: 64-89%) and 95.8% (95% CI: 90-100%) respectively. 
Thirteen pts presented LR failures, of which 4 had isolated local 
failure, 4 had isolated regional failure, 2 had local and regional 
failures, and 3 had simultaneous LR and distant relapses. Of 13 pts 
with LR relapse, only 1 (8%) had marginal failure, with the remaining 
92% failing truly in-field within the high-dose region. No patient 
recurred in vicinity of spared PG, SMG or OC. Surgical salvage for LR 
failure was attempted in 5 pts. Contralateral PG was spared in 98% of 
pts and ipsilateral PG in 54%. Concerning SMGs, 18 (26%) contralateral 
glands were spared and the ipsilateral SMG was spared in 5 pts. In 
other 13 (19%) pts doses to the SMGs below 50 Gy were obtained. The 
OC was spared to a dose ≤40 Gy in 26 pts (37%). None of the pts 
developed permanent xerostomia higher than grade 2 at the last 
follow-up visit. 
Conclusions: The majority of LR failures occurred in-field within the 
high dose region. Sparing SMGs and OC in addition to PGs does not 
seem to jeopardize the LR control in HNC IMRT.  
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Purpose/Objective: To evaluate the role of pretreatment dual-phase 
18F-FDG-PET maximum standardized uptake (SUVmax) in predicting 
the outcome of nasopharyngeal carcinoma (NPC). 
Materials and Methods: A total of 140 patients with newly diagnosed 
NPC were prospectively treated with IMRT plus neoadjuvant or 
concurrent chemotherapy between January 2006 and December 2008. 
Pretreatment SUVmax at 60 minutes (SUV1) and 150 minutes (SUV2) 
after injection of 18F-FDG were collected. We investigated the effects 
of SUVmax of primary tumor (SUV1-primary, SUV-2-primary) and neck 
lymph nodes (SUV1-neck, SUV2-neck) on locoregional failure-free 
survival (LRFFS), distant metastasis failure-free survival (DMFFS) and 
overall survival (OS). 
Results: In univariate analysis, the 5-year rate of OS for patients with 
SUV1-primary <12.9 was significantly higher than those with SUV1-
primary ?12.9 (87.0% and 72.2%, p=0.044). SUV2-primary, SUV1-neck 
and SUV2-neck did not affect OS significantly. All SUVs of primary 
tumor and neck lymph nodes have significant effects on DMFFS (SUV1-
primary < vs. ?12.5=89.1% vs. 70.8%, p=0.004; SUV2-primary < vs. 
?12.8=88.6% vs. 76.4%, p=0.022; SUV1-neck < vs. ?8.1=91.0% vs. 71.8%, 
p=0.003; and SUV2-neck < vs. ?3.7=94.7% vs. 80.5%, p=0.024, 
respectively). All SUVs had no significant effect on LRFFS. In 
multivariate analysis, except for N stage, SUV1-primary, SUV2-primary 
and SUV1-neck were significantly independent predictors of DMFFS 
(hazard ratio=4.313, 95% CI=1.447~12.855, p=0.009; hazard 
ratio=4.399, 95% CI=1.514~12.785, p=0.006; and hazard ratio=3.769, 
95% CI=0.985~14.420, p=0.053, respectively). 
Conclusions: The SUV1- primary predicts OS by univariate analysis. 
The SUV1-primary, SUV2-primary and SUV1-neck were independently 
prognostic factors of distant failure.  
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Purpose/Objective: To create Helical Tomotherapy (HT) plans for t 
treating patients with oropharyngeal cancer (OPC) with the same 
treatment time as RapidArc (RA) Volumetric Modulated Arc Therapy 
(VMAT).  
Materials and Methods: We made both a double arc RA plan on 
Eclipse and a standard HT plan on TomoHDTM according to the ICRU 83 
guidelines in 5 OPC patients. In 32 fractions, a simultaneous 
integrated boost technique was planned to deliver 69.12 Gy (2,16 Gy / 
fraction) to the high risk volume (PTV of the GTV + 1cm) and 56 Gy 
(1.75 Gy / fraction) to the PTV of the remaining primary tumor region 
and the bilateral elective lymph node regions. Guidelines for all the 
organs at risk (OARs) were given. By modifying the beam width from 
2.5 cm to 5.0 cm, elevating the pitch and lowering the modulation 
factor, we created 'Tomo Fast (TF) plans in which treatment times 
were equal to those in the RA plans. The homogeneity index (HI), the 
conformity index (CI), the mean dose, the Dnear-max (D2) and the 
Dnear-min (D98) of the PTVs were analyzed as well as the mean dose 
and specific critical doses and volumes of 26 OARs . Differences 
between the individual plans of the treatment planning systems were 
analyzed using repeated measures ANOVA. 
Results: With a mean treatment time of 3.05 min for RA and 2.89 min 
for TF , PTVboost coverage was more homogeneous with TF (mean HI 
.07; SE .01) than with RA (mean HI .10; SE .01). while PTVelective was 
most homogeneous with RA. Mean doses to the parotid glands were 
identical for RA and TF: 25.62 Gy and 25.34 Gy for the contralateral 
and 32.02 Gy and 31.96 Gy for the ipsilateral gland, respectively. 
Spinal cord, cricopharyngeal muscle and cranial part of the esophagus 
received a lower mean dose when planned with TF, the glottic larynx 
when planned with RA. V20 of the lungs, mean dose of inner ears, 
brain and eyes, and the integral dose were higher with TF than with 
RA, probably due the 5 cm beam width related cranial-caudal gradient 
extension. For details, see enclosed Table. 
 
  
Conclusions: This study shows that it is possible to treat OPC patients 
with TF as fast as with RA while giving comparable target coverage 
and sparing of most critical organs. However, with TF the higher dose 
to the organs at the cranial and caudal end of the target volume and 
the higher integral dose, both due to the extended cranial-caudal 
gradient, needs consideration. Moreover, compared to regular HT, 
both these faster techniques lose a (major) part of HT’s OAR sparing 
capacity. 
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Purpose/Objective: Optimisation of swallowing outcome after 
curative radiotherapy is multifaceted and requires maintaining the 
functional integrity of multiple pharyngeal axis structures. Recent 
dose/volume/outcome data (DVO)demonstrates a correlation between 
laryngeal dose and late dysphagia complication. Accurate and reliable 
DVO data demands consistent delineation, yet several guidelines for 
the delineation of the pharyngeal axis exist. This is a comparative 
study of two delineation guidelines of the pharyngeal axis and the 
implications that differences between them may have on dosimetry.  
Materials and Methods: The pharyngeal axis (inclusive of superior 
(SPCM), middle (MPCM) and inferior pharyngeal constrictors (IPCM), 
cricopharyngeus(CP), oesophageal inlet (OI)) were retrospectively 
contoured by one clinician on five consecutive patients with SCC head 
and neck, utilising two different sets of delineation guidelines (G1 (1) 
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& G2 (2)). Dice similarity coefficients (DSC) were used to compare G1 
and G2 spatial similarity. G1 and G2 defined structures were 
subsequently analysed for planned dose discrepancy. 
1. Christianen ME, Langendijk JA, WesterlaanHE, et al. Delineation of 
organs at risk involved in swallowing for radiotherapy treatment 
planning. Radiother Oncol 2011;101:394-402. 
2. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in 
patients with cancer of the oropharynx are significantly affected by 
the radiation therapy dose to the superior and middle constrictor 
muscle: a dose-effect relationship. Radiother Oncol 2007;85:64-73. 
Results: Differences in G1 and G2 delineation guidelines reported DSC 
values less than 0.5, indicating poor spatial correlation- SPCM 
(DSC=0.09±0.09, range of 0.02-0.22), MPCM (DSC=0.47±0.16, 
range:0.26 to 0.63), IPCM (DSC=0.34±0.12, range: 0.19 to 0.49), CP 
(DSC=0.33±0.12,range: 0.12 to 0.41), and OI (DSC=0.15±0.13, range: 0 
to 0.31). This difference in delineation led to dose differences for 
each structure (Dmean), shown inTable I, with some structures 
impacted by up to 13.9 %. Such variation is indicative of the variable 
proximity of the pharyngeal axis to areas of steep dose heterogeneity. 
In general, the range of per-structure dose differences across all 
patients was large, showing that indicated complication probability 
can be highly dependent upon which guideline is chosen for clinical 
use. 
Table 1. Dose difference of Dmean between structures delineated 
with G1 and G2 guidelines 
  
Conclusions: Whilst this study reported varying degrees of correlation 
between planned dosimetry and spatial incongruity, it highlights the 
potential of dosimetric variability with inconsistent delineation 
guidelines and the mandate to investigate with a larger patient cohort 
across multiple critical structures. When critical structures lie in close 
proximity to areas of steep dose heterogeneity, delineation disparity 
and subsequent dose discrepancy is of greater significance. Integrity 
of future DVO data demands a consensus on delineation guidelines to 
ensure recommendations are robust in clinical practice. 
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Purpose/Objective: To evaluate the effect of post-radiation adjuvant 
chemotherapy with oral tegafur-uracil in patients with high-risk 
nasopharygeal carcinoma (NPC) after combined chemoradiotherapy. 
Materials and Methods: Our definition of high-risk NPC included 
patients with 1) neck node > 6 cm; 2) supraclavicular node metastasis; 
3) skull base destruction/intracranial invasion plus multiple nodes 
metastasis; or 4) multiple neck nodes metastasis with one of nodal 
size > 4 cm. One hundred and sixty-three high-risk NPC patients 
finished full-course of concurrent chemoradiotherapy or neoadjuvant 
chemotherapy plus radiotherapy. Post-radiation adjuvant 
chemotherapy with oral tegafur-uracil (200 mg twice daily) for 12 
months was recommended to evaluate its impact on subsequent tumor 
relapse. One hundred and forty-one patients agreed to receive 
adjuvant oral tegafur-uracil. Twenty-two patients who refused 
adjuvant chemotherapy were served as a control. 
Results: After a median follow-up of 38 months, 32 of 141 (22.7%) 
patients with adjuvant tegafur-uracil developed tumor relapse later, 
whereas 59.1% (13/22) patients without adjuvant tegafur-uracil had 
tumor relapse. The progression-free survival rates were significantly 
higher in patients with adjuvant tegafur-uracil than those without 
adjuvant tegafur-uracil (P<0.0001). The adjuvant chemotherapy of 
tegafur-uracil was well-tolerated with no grade 3/4 toxicity. 
Conclusions: Post-radiation adjuvant chemotherapy with oral tegafur-
uracil for 12 months significantly reduced the relapse rate in high-risk 
NPC patients.  
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Purpose/Objective: A four-dimensional (4D) cone-beam CT (CBCT) is 
widely implemented in the precise radiation therapy of lung cancer 
treatment.In this study, we present a novel verification system for an 
image-guided radiation therapy (IGRT) by using in-treatment 4D CBCT 
acquired during Volumetric Modulated Arc Therapy (VMAT). 
Materials and Methods: A Stereotactic Body Radiation Therapy (SBRT) 
for lung cancer patient was performed by Elekta Synergy with a single-
arc VMAT. During the beam delivery, cone-beam projection images 
were sequentially acquired. A respiratory signal was reproduced by an 
image-based phase recognition technique computed with a normalized 
cross correlation between adjacent projections.Then, in-treatment 4D 
CBCT with four phase bins was reconstructed by in-house software and 
the CBCT sets were exported into the treatment planning system 
(TPS). After a registration of the CBCT center with the isocenter 
position in the corresponding treatment plan, the tumor location 
visualized in the CBCT for each phase was compared with that in the 
treatment plan. To see how this system works well, in particular, the 
center-of-mass (COM) of gross tumor volume (GTV) for maximum 
inhalation and exhalation for 10 patients was compared with those 
estimated by the planning CT. 
Results: The differences in maximum inhalation were 0.3 ± 1.3 mm, 
0.2 ± 1.7 mm, -0.7 ± 3.1 mm for the LR, AP, and CC directions, 
respectively,whereas the differences in maximum exhalation were 0.1 
± 1.3 mm, -0.4 ± 1.8 mm, -0.1 ± 1.9 mm for the LR,AP, and CC 
directions, respectively. 
Conclusions: In-treatment 4D CBCT is a direct method for 
quantitatively assessing the intrafractional location of a moving 
target. It was feasible to verify the tumor location during actual beam 
delivery with the system developed by using in-treatment 4D CBCT.  
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Purpose/Objective: Three–dimensional non-coplanar conformal 
radiotherapy (3-DNCCRT) has recently been considered promising for 
the treatment of stage I non-small cell lung cancer (NSCLC). Usually, 
it is performed in the form of SBRT using 10 – 20Gy fraction dose. 
However, this method is considered to be contraindicated for so-
called central tumors because of the toxicity of serial organs, such as 
bronchus, large vessels, etc. We have been treating these tumors with 
relatively small fraction dose (usually 3Gy) keeping BED10 at the 
similar level to that of SBRT. In this study, we analyzed our 10-year 
results. 
Materials and Methods: Eligibility criteria were as follows: maximum 
tumor diameter not greater than 5cm, PS between 0 and 2, and no 
limitation regarding age and pulmonary function. Radiotherapy was 
given with 6MV photon beam by fixed 10 non-coplanar conformal 
beams to a total dose of 75Gy in 25 fractionsin 5 weeks. Irradiation 
was aiming at the ITV with proper margins. No ENI was given. Between 
Jan. 2002 and Dec. 2010, 111 eligible cases were treated. Age ranged 
from 53 to 93 (median 78). The male/female ratio was 80/31. There 
were 64T1 tumors and 47 T2. Twenty-four tumors were sqcca, 71 
adenoca, and 16 others.There were 92 inoperable cases (83%), among 
them poor pulmonary function was in 66 (59%), and 19 operable cases, 
who refused operation. The average tumor size was 3.0 cm (range; 1.2 
to 5.0 cm). There were 102 PS 1 and 9 PS 2 cases. Among the entire 
cases, 46 cases were central tumors and the other 65 were peripheral 
tumors. Median follow-up period was 46 months.  
Results: Three- and 5-year local control rate (LC), overall survival 
rate (OS), cause-specific survival rate, and relapse-free survival rate 
for overall cases were, 85% and 85%, 67% and 50%, 79% and 65%, and 
56% and 41%, respectively. Three-year LC and OS for T1 and T2 cases 
were 87%, 66%, and 87%, 69%, respectively (n.s.). Three-year LC and 
OS for central and peripheral tumors were 85%, 70%, and 86%, 66%, 
respectively (n.s.). Three- and 5-year OS for operable and inoperable 
